Scinovex
article Open AccessTop 1% cited

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

Hepatology · 2018 · Vol. 67(4) · pp. 1560–1599
Norah A. TerraultAnna S. LokBrian J. McMahonKyong‐Mi ChangJessica HwangMaureen M. JonasRobert S. BrownNatalie BzowejJohn B. Wong

Abstract

This AASLD 2018 Hepatitis B Guidance is intended to complement the AASLD 2016 Practice Guidelines for Treatment of Chronic Hepatitis B The 2018 updated guidance on chronic hepatitis B (CHB) includes (1) updates on treatment since the 2016 HBV guidelines (notably the use of tenofovir alafenamide) and guidance on (2) screening, counseling, and prevention; (3) specialized virological and serological tests; (4) monitoring of untreated patients; and (5) treatment of hepatitis B in special populations, including persons with viral coinfections, acute hepatitis B, recipients of immunosuppressive therapy, and transplant recipients.

Hepatitis B Virus StudiesLiver Disease Diagnosis and TreatmentHepatitis C virus researchMedicineChronic hepatitisHepatitis BHepatitisVirologyInternal medicineIntensive care medicineGastroenterologyVirus

MeSH terms

Hepatitis B, ChronicAdultAntiviral AgentsChildCounselingHumansMass ScreeningHepatitis B Vaccines

Funding

  • Bristol-Myers Squibb
  • American Association for the Study of Liver Diseases
  • Gilead Sciences
  • Allergan
Citations
4,171
FWCI
269.99
field-weighted impact
References
282
Percentile
100%
vs. same field & year
Citations per year
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.